Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe

Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe

2025.03.21
Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the University of Navarra Medical School, Spain, share their insights into the latest breakthroughs in liver cancer treatment. They discuss the evolving role of immunotherapy, targeted therapy, and the importance of global collaboration in shaping the future of liver cancer care. Watch the full conversation to gain expert perspectives on emerging treatment strategies, biomarker-driven approaches, and the future of liver cancer therapy.
Dr. Kefeng Ding: Exploration of the Balance between Radical Resection and Functional Preservation in Colorectal Cancer Treatment with LISH Procedure| Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

Dr. Kefeng Ding: Exploration of the Balance between Radical Resection and Functional Preservation in Colorectal Cancer Treatment with LISH Procedure| Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

2025.03.21
At the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Kefeng Ding from The Second Affiliated Hospital  Zhejiang University School of Medicine presented innovative advancements in laparoscopic ileocecal-sparing hemicolectomy (LISH) for right-sided colon cancer, highlighting its potential to balance oncologic radicality with functional preservation. His insights provide valuable guidance for clinical practice, promoting precision surgery and organ function preservation in colorectal cancer treatment. Oncology Frontier presents key highlights from his lecture.
Dr. Xiujuan Qu: Breakthroughs in Precision Treatment for Advanced Colorectal Cancer – KRAS G12C Inhibitors Leading the Way

Dr. Xiujuan Qu: Breakthroughs in Precision Treatment for Advanced Colorectal Cancer – KRAS G12C Inhibitors Leading the Way

2025.03.21
With the discovery of molecular targets and the development of corresponding targeted inhibitors, the treatment of metastatic colorectal cancer (mCRC) is becoming increasingly precise and personalized. At the recent 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Xiujuan Qu from The First Hospital of China Medical University shared the latest advancements in precision treatment for advanced colorectal cancer, including novel therapeutic strategies and the promising role of KRAS G12C inhibitors.
Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025

Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025

2025.03.20
New research led by Dr. Andrea Mastrangelo at Centre Hospitalier Universitaire Vaudois unveils a distinct transcriptomic signature in lymph node (LN) HIV-specific CD8 T cells of HIV controllers. Unlike chronic HIV-infected individuals (CHI), controllers exhibited an enriched population of stem-like CD8 T cells marked by TCF7, IL7R, and BACH2, which may contribute to proliferative potential and effective viral control.